| COVID-19 |
1 |
1 |
| Disability |
0 |
0.58 |
| Receptors |
0 |
0.44 |
| Anticoagulation Therapy |
0 |
0.29 |
| Hospital |
0 |
0.29 |
| Plasma |
0 |
0.29 |
| Quality of Life |
0 |
0.27 |
| Antiplatelet Agent |
0 |
0.22 |
| Pneumonia |
0 |
0.22 |
| Corticosteroids |
0 |
0.14 |
| Grant |
0 |
0.14 |
| Intensive Care Unit |
0 |
0.12 |
| Biologic Therapy |
0 |
0.08 |
| Cerebrovascular Accident |
0 |
0.08 |
| Complementary and Alternative Medicine |
0 |
0.08 |
| Antiviral Agents |
0 |
0.07 |
| Aspirin |
0 |
0.07 |
| Canada |
0 |
0.07 |
| Chronic Disease |
0 |
0.07 |
| Community-Acquired Pneumonia |
0 |
0.07 |
| Geriatrics |
0 |
0.07 |
| Heart |
0 |
0.07 |
| Integrative Medicine |
0 |
0.07 |
| Interleukin |
0 |
0.07 |
| Organ Failure |
0 |
0.07 |
| Pandemic |
0 |
0.07 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.07 |